Seqens CDMO, a pharmaceutical manufacturer of new chemical entities (NCEs), active pharmaceutical ingredients (APIs) and other specialty chemical products, announced that Bob Huang has joined as Managing Director for North America. The company is a division of Seqens, a billion-dollar global leader in pharmaceutical synthesis and specialty ingredients with19 industrial sites and 3,000 employees worldwide, including more than 300 scientists, engineers and other experts.
Bob Huang is responsible for expanding Seqens CDMO NA’s presence as the ideal manufacturing partner with global capabilities. His immediate plans are to increase the company’s manufacturing capacity and R&D capabilities in the U.S. through physical expansion, as well as staff growth and new cutting-edge technology and equipment. He also will continue to integrate U.S. operations into Seqens’ global organizational structures and corporate quality and safety cultures
“With decades of experience in research and development, manufacturing and commercial operations with leading pharma firms, such as Sanofi, Bob has the right experience and vision to direct our continued innovation and growth across North America,” said Pierre Luzeau, CEO of Seqens Group, parent company of Seqens CDMO.
“Seqens CDMO NA’s location in the Boston area, a world-renowned life sciences hub, provides us with enormous opportunities to provide our expertise, as well as our spirit of innovation in the community to become a global CDMO destination,” said Bob Huang, Managing Director, Seqens CDMO North America. “Since its founding, Seqens has been at the forefront of innovative drug development and manufacturing and I see significant value for our customers in being able to integrate the specialized expertise of our North American operations with that of our global industrial and regulatory resources to offer seamless technology transfer among our plants for API and pharmaceutical intermediates manufacturing.”
Before joining Seqens CDMO NA, Huang held both senior-level business and technical positions with Sanofi for more than 20 years. His most recent position was senior director of U.S. external collaboration, where he led the U.S. organization in supporting Sanofi’s global business development and licensing strategy and external collaboration activities targeting preclinical, clinical and commercial stage assets. Prior to that he was head of North American API contract manufacturing, overseeing Sanofi’s CDMO and API sales activity.
With a PhD in organic chemistry and MBA training, Huang has developed broad technical, business and management experience in pharmaceutical development and manufacturing, that will enable him to achieve Seqens CDMO NA’s ambitious business objectives.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!